Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways

INTRODUCTION: Osteoporosis is an osteolytic bone condition characterized by decreased bone strength and increased bone fragility. It is the result of elevated formation or activity of bone-resorbing osteoclasts. Although current therapeutic agents are efficacious against osteoclast-mediated bone los...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Drug Des Devel Ther
Auteurs principaux: Li, Xuedong, Lin, Xixi, Wu, Zuoxing, Su, Yuangang, Liang, Jiamin, Chen, Runfeng, Yang, Xue, Hou, Lei, Zhao, Jinmin, Liu, Qian, Xu, Feng
Format: Artigo
Langue:Inglês
Publié: Dove 2021
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7800467/
https://ncbi.nlm.nih.gov/pubmed/33442237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S283694
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires